Literature DB >> 7686122

Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.

J M Pawlotsky1, L Deforges, S Bretagne, C André, J M Métreau, V Thiers, E S Zafrani, M Goossens, J Duval, J P Mavier.   

Abstract

Hepatitis C virus (HCV) has been shown to induce anti-liver-kidney microsomal-1 (LKM1) antibody positive chronic active hepatitis, simulating type 2 autoimmune chronic active hepatitis. The cases of five patients presenting with features of type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis and extrahepatic autoimmune manifestations, in whom immunosuppressive treatment had no effect on liver disease are presented. In these patients, HCV infection could be shown by the presence in serum of anti-HCV antibodies and HCV-RNA detected by polymerase chain reaction. These cases suggest the following: (a) chronic HCV infection can mimic type 1, as well as type 2, autoimmune chronic active hepatitis; (b) HCV infection might be systematically sought in patients presenting with features of type 1 autoimmune chronic active hepatitis, with special care in patients who are unresponsive to immunosuppressive treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686122      PMCID: PMC1374014          DOI: 10.1136/gut.34.2_suppl.s66

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Hepatitis C virus replication in 'autoimmune' chronic hepatitis.

Authors:  S Magrin; A Craxi; C Fabiano; G Fiorentino; P Almasio; U Palazzo; G Pinzello; G Provenzano; L Pagliaro; Q L Choo
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

3.  Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity.

Authors:  M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

4.  Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

Authors:  S Mishiro; Y Hoshi; K Takeda; A Yoshikawa; T Gotanda; K Takahashi; Y Akahane; H Yoshizawa; H Okamoto; F Tsuda
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

5.  Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders.

Authors:  L Todros; G Touscoz; N D'Urso; M Durazzo; E Albano; G Poli; M Baldi; M Rizzetto
Journal:  J Hepatol       Date:  1991-07       Impact factor: 25.083

6.  Anti-GOR and hepatitis C virus in autoimmune liver diseases.

Authors:  G Michel; A Ritter; G Gerken; K H Meyer zum Büschenfelde; R Decker; M P Manns
Journal:  Lancet       Date:  1992-02-01       Impact factor: 79.321

7.  Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease.

Authors:  J Haddad; P Deny; C Munz-Gotheil; J C Ambrosini; J C Trinchet; D Pateron; F Mal; P Callard; M Beaugrand
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

8.  Reinfection of liver graft by hepatitis C virus after liver transplantation.

Authors:  C Féray; D Samuel; V Thiers; M Gigou; F Pichon; A Bismuth; M Reynes; P Maisonneuve; H Bismuth; C Bréchot
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

9.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

Authors:  I G McFarlane; H M Smith; P J Johnson; G P Bray; D Vergani; R Williams
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

10.  Type 2 autoimmune hepatitis and hepatitis C virus infection.

Authors:  M Lenzi; G Ballardini; M Fusconi; F Cassani; L Selleri; U Volta; D Zauli; F B Bianchi
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

  10 in total
  3 in total

1.  Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer.

Authors:  R Biselli; D Vaira; R Nisini; M Miglioli; L Menegatti; L Barbara; R D'Amelio
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

2.  Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.

Authors:  J M Pawlotsky; A Fleury; V Choukroun; L Deforges; F Roudot-Thoraval; P Aumont; J Duval; D Dhumeaux
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

3.  The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report.

Authors:  Rita Lebano; Valerio Rosato; Mario Masarone; Marco Romano; Marcello Persico
Journal:  BMC Res Notes       Date:  2014-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.